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stantially prolong disease-free survival and cause a moderate 
increase in overall survival. In the current meta-analysis, a 
significant survival benefit was only seen with regard to me-
dian survival, but not for the 5-year survival rate. The optimal 
chemotherapy regimen in the adjuvant setting as well as in-
dividualized treatment strategies (also including modern 
chemoradiotherapy regimens) still remain to be defined.
 Copyright © 2008 S. Karger AG, Basel
 Introduction
 Pancreatic cancer is currently the 4th to 5th most fre-
quent cause of solid tumor deaths in Western industrial-
ized countries. Despite advances in the understanding of 
the underlying biology, improvements of diagnostic tools 
and the development of new effective agents, the major-
ity of patients diagnosed with pancreatic cancer still have 
a fatal outcome, and 5-year survival rates rarely exceed 
5%  [1] .
 The minority of pancreatic cancer patients present 
with resectable disease at first diagnosis. Approximately 
10–15% of patients undergo partial or complete pancre-
aticoduodenectomy as the established standard of care 
 [2, 3] . Morbidity and mortality associated with the 
Kausch-Whipple procedure have decreased during the 
last 2 decades, especially in high-volume centers. Despite 
the curative intent of surgery and optimized application 
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 Abstract
 Background: In patients undergoing surgery for resectable 
pancreatic cancer prognosis still remains poor. The role of 
adjuvant treatment strategies (including chemotherapy and 
chemoradiotherapy) following resection of pancreatic can-
cer remains controversial.  Methods: A Medline-based litera-
ture search was undertaken to identify randomized con-
trolled trials that evaluated adjuvant chemotherapy after 
complete macroscopic resection for cancer of the exocrine 
pancreas. Five trials of adjuvant chemotherapy were eligible 
and critically reviewed for this article. A meta-analysis (based 
on published data) was performed with survival (median 
survival time and 5-year survival rate) being the primary 
endpoint.  Results: For the meta-analysis, 482 patients were 
allocated to the chemotherapy group and 469 patients to 
the control group. The meta-analysis estimate for prolonga-
tion of median survival time for patients in the chemothera-
py group was 3 months (95% CI 0.3–5.7 months, p = 0.03). 
The difference in 5-year survival rate was estimated with 
3.1% between the chemotherapy and the control group 
(95% CI –4.6 to 10.8%, p  1 0.05).  Conclusion: Currently avail-
able data from randomized trials indicate that adjuvant che-
motherapy after resection of pancreatic cancer may sub-
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of supportive therapy, median survival after resection of 
pancreatic cancer remains in the range of 11–20 months 
and is associated with a 5-year survival of 7–25%  [3, 4] . 
Primary sites of disease recurrence are the retroperito-
neum (34–87%), the peritoneum (19%-53%), the liver 
(38–73%) and extra-abdominal sites such as the lungs (8–
29%)  [3] . Recent efforts to improve outcome by more rad-
ical resection procedures or extensive lymphadenectomy 
have not improved the course of disease, which can be 
explained by early distant metastasis occurring in most 
patients, while isolated local recurrence is less frequent 
 [5] . Important predictors of recurrence include tumor 
size (defined by T stage), nodal involvement, positive re-
section margins, and vascular, lymphatic and perineural 
invasion  [6] . As the poor prognosis of patients with pan-
creatic cancer is primarily determined by systemic and 
not local failure, it becomes self-evident that adjuvant 
treatment strategies should predominantly focus on an 
improvement of systemic treatment.
 The aim of the present article was to systematically 
review randomized controlled trials that evaluated the 
role of adjuvant chemotherapy after macroscopically 
complete resection of pancreatic cancer. Additionally, a 
meta-analysis (based on published data) for adjuvant 
chemotherapy was conducted, which also included the 
survival data from the recently published CONKO-001 
study  [7] .
 Methods
 Selection Criteria for Trials Included in the Systematic Review 
and Meta-Analysis
 This analysis only included randomized clinical trials that 
were conducted in patients with histologically proven cancer of 
the exocrine pancreas. In each trial, patients underwent surgery 
with curative intent (R0 or R1 resection, negative or positive nod-
al status); adjuvant treatment consisted of chemotherapy alone or 
chemoradiotherapy (CRT) followed by sequential full-dose che-
motherapy (only in the ESPAC-1 study). Trials were identified by 
a literature search using the Medline database. In addition, rele-
vant abstract publications from scientific meetings (for example 
the American Society of Clinical Oncology) were included, and 
previous reviews and meta-analyses were screened for any other 
relevant trials.
 Statistical Methods for Meta-Analysis
 A meta-analysis of randomized trials for adjuvant chemother-
apy was performed on the basis of published data. The endpoint 
of this meta-analysis was survival, defined by median survival 
time and the 5-year survival rate. Five randomized trials met the 
criteria for the meta-analysis ( table 1 ); 4 of these 5 trials compared 
chemotherapy versus observation only, whereas the ESPAC-1 tri-
al compared chemotherapy versus no chemotherapy and CRT 
versus no CRT using a 2  ! 2 factorial design. Overall, 482 patients 
were allocated to the chemotherapy group, whereas 469 patients 
were allocated to the control group (observation and no chemo-
therapy).
 Meta-analyses of differences in absolute 5-year survival rates 
between the chemotherapy and control groups were performed 
as follows: the published 5-year survival rates for the chemother-
apy,   treat,k , and control,   control,k , groups of each study were ex-
tracted from the published results and the standard error for 
each calculated by published numbers at risk at 5 years using the 
formula of Peto et al.  [8] .   The variance of the difference in 5-year 
survival rates,   k  =   treat,k  –   control,k , equals the sum of the squared 
standard errors and its inverse is used as the study weight, w k , for 
study k for the k = 1, …,  K studies, where  K = 5. A test of hetero-
geneity of study effects was performed by comparing the statistic 
Q   =    k (  k    –    ) 2    for      =    k w k  k /  k w k    to   a    2    distribution   with  K 
– 1 degrees of freedom  [9] . If the test was not significant, the 
analysis was performed assuming a normal fixed effects model 
with known study-specific variances. Otherwise, the results 
were analyzed using a normal random effects model with fixed 
study-specific variances and a random between-study variance 
component,   2 , to compensate for the heterogeneity between the 
studies. Meta-analysis results are reported in terms of average 
difference,   , with 95% confidence interval (CI). All statistical 
tests were performed at the 2-sided 0.05 level and all statistical 
computations were done using the R statistical package (version 
2.4.1).
 Meta-analyses of differences in median survival times be-
tween the chemotherapy and control groups were performed 
analogously, but using published median survival times and an 
approximation to the standard error of median times provided by 
assumption of an exponential distribution (standard error of me-
dian = median/square root of number of events) for studies that 
did not publish CI for the medians  [10, 11] . Log transformation of 
median survival times for the Wald-type analysis gave very simi-
lar results, so no transformation was used.
 Results
 Randomized Trials for Adjuvant Chemotherapy
 In view of the high rate of systemic relapse in patients 
after resection with curative intent, there is a clear scien-
tific rationale to investigate systemic adjuvant chemo-
therapy in pancreatic cancer.  Table 1 summarizes surviv-
al results from randomized trials investigating adjuvant 
chemotherapy for patients with resected pancreatic can-
cer.
 Norwegian Trial
 Bakkevold et al.  [10] were among the first to investi-
gate adjuvant chemotherapy in a small randomized mul-
ticenter trial: systemic chemotherapy with 5-fluorouracil 
(5-FU) 500 mg/m 2 , doxorubicin 40 mg/m 2  and mitomy-
cin C 6 mg/m 2  (applied every 3 weeks for 6 cycles; FAM 
regimen; n = 30) was compared to observation alone (n = 
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31) in patients with pancreatic cancer and carcinomas of 
Vater’s ampulla. Application of adjuvant chemotherapy 
for a planned duration of 4.5 months induced a signifi-
cant improvement of median survival (23 vs. 11 months, 
p = 0.02), but the 5-year survival was not significantly 
changed (4 vs. 8%, p = 0.10, generalized Wilcoxon test).
 Japanese Trials
 Kosuge et al.  [11] recently reported a randomized trial 
where R0 resected patients either received 2 cycles of 5-
FU (500 mg/m 2 /day, days 1–5) plus cisplatin (80 mg/m 2 , 
day 1) every 4–8 weeks (n = 45) or were attributed to an 
observational arm (n = 44). No significant improvement 
of median survival (12.5 vs. 15.8 months) was reported; 
also, no significant advantages for the treatment arm 
with regard to the 5-year survival rate (26.4 vs. 14.9%, 
p = 0.94)   and   the   recurrence rate at 5 years (73.6 vs. 
80.8%, p = 0.80) were observed.
 Takada et al.  [12] performed a large randomized study 
comparing postoperative chemotherapy to observation 
in 508 patients with resected pancreaticobiliary cancers. 
Within this trial, 173 patients with pancreatic cancer 
were randomly assigned to either adjuvant chemotherapy 
using the MF regimen (mitomycin C 6 mg/m 2  on the day 
of surgery plus 5-FU 310 mg/m 2  for 5 days during post-
operative weeks 1 and 3, followed by daily oral 5-FU 100 
mg/m 2  from postoperative week 5 until recurrence of dis-
ease) or observation. In 158 eligible patients, adjuvant 
chemotherapy with MF (n = 81) neither improved the 5-
year disease-free survival (DFS) rate (8.6 vs. 7.8%, p = 
0.84) nor the 5-year overall survival rate (11.5 vs. 18.0%, 
p = not significant) compared to patients in the control 
group (n = 77).
 ESPAC-1
 In 2001 and 2004, the European Study Group of Pan-
creatic Cancer (ESPAC) reported their results from a 
large randomized multicenter trial performed in the ad-
juvant setting (ESPAC-1 study)  [13, 14] . After R0/R1 re-
section, patients were randomized to 1 of 4 treatment 
arms: adjuvant chemotherapy (5-FU 425 mg/m 2  and fo-
linic acid 20 mg/m 2 , days 1–5, monthly for 6 months) or 
CRT [analogous to the Gastrointestinal Tumor Study 
Group (GITSG) regimen], a sequence of CRT and chemo-
therapy or observation only. While 541 patients were ran-
domized overall  [13] , only 289 patients were included into 
the 2  ! 2 factorial design comparing chemotherapy ver-
sus no chemotherapy or CRT versus no CRT  [14] .
 At a median follow-up of 47 months, the analysis of 
the 2  ! 2 factorial design patients indicated a median 
survival of 20.1 months for the chemotherapy group and 
15.5 months for the no chemotherapy group (hazard ra-
tio = 0.71, 95% CI 0.55–0.92, p = 0.009). Also, the esti-
mated 5-year survival rate was greater in the chemother-
apy group (21 vs. 8%)  [14] . The median time to disease 
recurrence was 15.3 months among patients in the che-
motherapy arm and 9.4 months among patients who did 
not receive chemotherapy (p = 0.02). This trial has been 
criticized not only for statistical, but also for methodolog-
ical flaws, including the fact that in the chemotherapy 
 Table 1. Survival results from randomized trials comparing adjuvant chemotherapy to observation [7, 10, 11, 12] or to no chemo-
therapy [14]
 Reference  Regimen  Duration of treat-
 ment, months 
 Subjects
 n 
 Median OS
 months 
 5-year OS
 % 
 Bakkevold et al. [10]  FAM regimen every 3 weeks for 6 cycles
 Observation 
 4.5 30
31 
 23*
 11 
4
8 
 Takada et al. [12]  MF regimen until disease recurrence
 Observation 
 NA 81
77 
 NA
 NA 
 11.5
 18.0 
 Kosuge et al. [11]  5-FU + cisplatin every 4–8 weeks for 2 cycles
 Observation 
 2–4 45
44 
 12.5
 15.8 
 26.4
 14.9 
 ESPAC-1 [14]  5-FU/FA on days 1–5 every 4 weeks for 6 cycles
 No chemotherapy 
 6  147
 142 
 20.1
 15.5** 
 21
8 
 CONKO-001 [7]  Gemcitabine weekly 3 times every 4 weeks for 6 cycles
 Observation 
 6  179
 175 
 22.1***
 20.2 
 22.5
 11.5 
 OS = Overall survival; FAM = 5-fluorouracil + doxorubicin + mitomycin C; MF = mitomycin C + 5-fluorouracil; 5-FU = 5-fluo-
rouracil; FA = folinic acid; NA = data not available. * p = 0.02 for median test and p=0.10 by Wilcoxon test; ** p = 0.009 for Cox pro-
portional hazards ratio test; *** p = 0.06 for log rank test. 
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arm only 50% of patients received treatment according to 
the protocol and that 17% of patients did not receive che-
motherapy at all. Thus, the data from the ESPAC-1 trial 
are highly suggestive, but not sufficient to derive a strong 
treatment recommendation.
 CONKO-001
 More recently, final results from the German CONKO-
001 trial were published; 368 patients were recruited into 
this trial, which compared chemotherapy with gem-
citabine (1,000 mg/m 2 , days 1, 8 and 15 every 4 weeks for 
6 months) administered within 6 weeks after R01/R1 re-
section to observation  [7] . The primary endpoint of this 
trial was DFS and the primary hypothesis an increase on 
chemotherapy of at least 6 months. The final results of 
this study showed a significant increase in DFS in the 
treatment group (13.4 months) compared to the observa-
tion only group (6.9 months, p  ! 0.001). However, at the 
time of evaluation, there was no significant difference in 
median survival between the 2 groups (gemcitabine vs. 
observation: 22.1 vs. 20.2 months, p = 0.06). The 5-year 
overall survival rate was estimated with 22.5% (gem-
citabine arm) versus 11.5% (observation arm). The au-
thors stated that these findings on survival may be ex-
plained, at least in part, by the fact that patients from the 
control group received gemcitabine upon disease recur-
rence as a standard of care in the palliative setting. Data 
from a nonpredefined subgroup analysis of CONKO-001 
are summarized in  table 2 . The beneficial effect of adju-
vant chemotherapy on DFS was demonstrated in all sub-
groups, classified by resection margin, nodal involve-
ment and T stage. The effect of gemcitabine treatment on 
DFS was most pronounced in the subgroup of node-neg-
ative patients (N–; difference in DFS,   DFS  = 14.4 months) 
and in patients with small primary tumors (T1–2;   DFS  = 
38.2 months). However, in light of the low numbers in the 
subgroups and with regard to the post hoc approach of 
this analysis, these results cannot be the basis for far-
reaching conclusions.
 In summary, adjuvant chemotherapy performed for 
4.5–6 months has induced a significant benefit in median 
survival in 2 trials: the Norwegian trial and the ESPAC-1 
trial. The CONKO-001 trial clearly met its primary end-
point and showed a significant prolongation of DFS by 
adjuvant chemotherapy with gemcitabine over 6 months. 
However, this study has failed to demonstrate a signifi-
cant prolongation of overall survival so far.
 Meta-Analysis of Randomized Trials for Adjuvant 
Chemotherapy
 Based on the selected trials identified by a systematic 
review of the literature, a meta-analysis was performed 
only for studies investigating adjuvant chemotherapy. 
Two meta-analyses have already been published on adju-
vant CRT  [15, 16] ; the meta-analysis by Stocken et al.  [15] 
also included randomized trials of adjuvant chemother-
apy, however, their study did not contain the recently 
published CONKO-001 data (368 patients)  [7] .
 Study-specific differences in 5-year survival rates be-
tween chemotherapy and control groups of trials includ-
ed in the meta-analysis are shown in  table 3 a; only the 
ESPAC-1 study demonstrates a statistically significant 
improvement in 5-year survival in the chemotherapy 
group according to the 95% CI computed by our method. 
There is statistically significant heterogeneity among the 
results of the 5 analyzed studies (p = 0.03), with all other 
studies except the ESPAC-1 study showing no statistical-
ly significant difference between the chemotherapy and 
 Table 2. Subgroup analysis (according to resection margin, nodal involvement and T stage) of DFS and overall 
survival from the CONKO-001 trial [7]
 Subgroup  Number  Median DFS, months  p value  Median OS, months  p value 
 Gem.  Obs.  Gem.  Obs.  Gem.  Obs. 
 R0
 R1 
 145
34 
 148
27 
 13.1
 15.8 
7.3
5.5 
 <0.001
 <0.001 
 21.7
 22.1 
 20.8
 14.1 
 0.18
 0.07 
 N–
 N+ 
52
 127 
48
 127 
 24.8
 12.1 
 10.4
6.4 
0.003
 <0.001 
 34.0
 18.5 
 27.6
 18.2 
 0.04
 0.44 
 T1–2
 T3–4 
25
 154 
24
 151 
 48.2
 12.9 
 10.0
6.7 
0.02
 <0.001 
 50.2
 20.5 
 27.6
 19.1 
 0.28
 0.11 
 OS = Overall survival; Gem. = gemcitabine; Obs. = observation only. 
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control groups. The combined meta-analysis estimate of 
a 5-year survival advantage of 3.1% in the chemotherapy 
group is also nonsignificant (p  1 0.05).  Figure 1 shows a 
funnel plot for the results of  table 3 a.
 For comparison of median survival times between 
chemotherapy and control, 4 studies listed in  table 3 b 
provided information for a meta-analysis. There was no 
statistically significant heterogeneity among the 4 studies 
(p = 0.07). The Bakkevold and ESPAC studies showed a 
significant improvement in median survival in the che-
motherapy arms and the CONKO-001 and Kosuge stud-
ies showed no significant difference in median survival 
between the 2 arms. A combined fixed effects meta-anal-
ysis indicated a statistically significant median survival 
extension on chemotherapy of 3 months (95% CI 0.3–5.7 
months, p = 0.03). Results from  table 3 b are displayed by 
a funnel plot in  figure 2 .
 We additionally assessed whether results for treatment 
differences in 5-year survival rates or median survival 
times depended on the total number of patients random-
ized to the study or the year of publication of the study 
( fig. 3 ). Studies published in the later years tended to have 
larger improvements on the chemotherapy arm in terms 
of 5-year survival rates but smaller improvements in me-
dian survival times. As the number of studies is small (5 
and 4), it is not possible to draw definitive conclusions on 
these trends.
 Table 3. Meta-analysis for survival of randomized trials investi-
gating adjuvant chemotherapy
 
 a Study-specific differences in 5-year survival rates and 95% CI
Study Difference (chemother-
apy – control) in 5-year
survival rate, %
95% CI, %
 Bakkevold et al. [10] –4.0  –10.9 to 2.9 
 Takada et al. [12] –6.5  –17.4 to 4.4 
 Kosuge et al. [11] 11.5  –10.0 to 33.0 
 ESPAC-1 [14] 13.0 0.6 to 25.4 
 CONKO-001 [7] 11.0 –1.8 to 23.8 
 Meta-analysis 1 3.1* –4.6 to 10.8 
 
 b Study-specific differences in median survival times and 95% CI
Study Difference (chemother-
apy – control) in median
survival times, months
95% CI 
months
 Bakkevold et al. [10] 12.0 1.5 to 22.5 
 Takada et al. [12] NA NA 
 Kosuge et al. [11] –3.3  –9.9 to 3.3 
 ESPAC-1 [14] 4.6 0.7 to 8.5 
 CONKO-001 [7] 1.9  –3.0 to 6.8 
 Meta-analysis 1 3.0** 0.3 to 5.7 
 NA = Data not available. * p > 0.05; ** p = 0.03.
 1  Meta-analysis combined estimate.  
–20 –10 0 10 20 30 40
Chemotherapy – control (5-year survival, %)
Kosuge
CONKO-001
ESPAC-1
Takada
Bakkevold
Meta
 Fig. 1. Differences in 5-year survival rate between chemotherapy 
and control groups and CI among the 5 studies included in the 
meta-analysis. Studies are ordered by length of CI (uncertainty in 
estimates). 
Bakkevold
Kosuge
CONKO-001
ESPAC-1
Meta
–10 –5 0 10 155 20 25
Chemotherapy – control (median survival, months)
 Fig. 2. Differences in median survival time between chemother-
apy and control groups and CI among the 4 studies included in 
the meta-analysis. Studies are ordered by length of CI (uncertain-
ty in estimates). 
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 Discussion
 The currently available data from randomized trials 
indicate that adjuvant chemotherapy may prolong DFS 
and even median overall survival. This observation is 
also underlined by our meta-analysis of 5 randomized 
trials that showed a significant prolongation of median 
survival with the use of adjuvant chemotherapy. How-
ever, the 5-year survival rate in the meta-analysis did not 
show a statistically significant benefit of adjuvant chemo-
therapy, possibly also caused by the low number of pa-
tients (number at risk) for this endpoint in each trial. No-
tably, most trials showing a benefit from adjuvant chemo-
therapy investigated a treatment duration of about 5–6 
months. By contrast, the trial reported by Kosuge et al. 
 [11] used a shorter treatment duration (2–4 months) and 
failed to show an improvement in median survival com-
pared to the observational arm. Considering that most 
recurrences occur within the first 2 years after surgery, 
there may be a good rationale to investigate prolonged 
adjuvant therapy in this highly malignant disease.
 Both recently published European trials were able to 
show a statistically significant and clinically meaningful 
benefit for DFS (CONKO-001) and time to disease recur-
rence (ESPAC-1) with the use of adjuvant chemotherapy. 
In both studies, the median gain for these endpoints was 
about 6 months, which is equivalent to the duration of 
adjuvant chemotherapy. However, the observed advan-
tage     for     DFS     and      time      to      disease      recurrence      translat-
ed into a significant overall survival benefit only in the 
ESPAC-1, but not the CONKO-001 study  [7, 14] . Thus, the 
question arises which reasons may be defined for these 
divergent observations: one major confounding factor 
that may influence survival results of adjuvant trials is 
the treatment patients received upon relapse. Palliative 
chemotherapy is known to provide a significant survival 
benefit in patients with advanced pancreatic cancer  [17] . 
None of the 2 studies, however, reported data on the treat-
ment that was applied to the study patients upon disease 
recurrence. Furthermore, the ESPAC-1 trial recruited pa-
tients between 1994 and 2000; thus, it is conceivable that 
a major part of patients did not have access to palliative 
therapy with gemcitabine, the current standard of care 
(introduced in 1997) in the palliative setting. Therefore, 
it may be argued that an early adjuvant chemotherapy has 
a comparable effect on overall survival as an identical late 
palliative chemotherapy (for example with single-agent 
gemcitabine), specifically when an effective second-line 
therapy is not defined  [7] .
 One main goal for adjuvant treatment strategies is to 
increase the number of patients that can be cured after 
surgery for different types of cancer (for example breast 
and colorectal cancer). Should this also be a (realistic) 
goal for patients with resected pancreatic cancer? This 
cancer is thought to show a systemic spread very early in 
the course of disease, and the majority of patients experi-
ence relapse by developing distant metastasis soon after 
curative-intent surgery. Induction of a long-term surviv-
al or even cure may be reflected by the 5-year survival 
rate of an adjuvant trial. However, the available data from 
randomized trials do not provide a clear and consistent 
superiority for this endpoint for patients with pancreatic 
cancer receiving adjuvant chemotherapy ( table 1 ). Even 
in studies that show a significant prolongation of median 
survival, the 5-year survival rate may be comparable  [10] . 
This observation is also underlined by the findings of our 
meta-analysis ( table 3 ).
 The role of CRT still remains controversial in pancre-
atic cancer. To date, 4 randomized trials have been per-
formed in the adjuvant setting  [14, 18–21] . The basis for 
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 Fig. 3. Five-year survival difference ( a ) and 
median survival difference ( b ; chemother-
apy – control) by year of publication with 
size of dots proportional to number of pa-
tients randomized to study. Included tri-
als: Bakkevold et al.  [10] , 1993 (n = 61); 
Takada et al.  [12] , 2002 (n = 158); ESPAC-1 
 [14] , 2004 (n = 289); Kosuge et al.  [11] , 2006 
(n = 89); CONKO-001  [7] , 2007 (n = 354). 
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2007;  25:  146–162.
adjuvant CRT was set in the 1980s when the GITSG per-
formed a small randomized trial showing that adjuvant 
CRT (5-FU-based split course external beam radiation 
therapy followed by a once-weekly bolus 5-FU mainte-
nance chemotherapy for 2 years) was more effective than 
observation, inducing an overall survival of 20 versus 11 
months  [18, 19] . However, it still remains unclear to which 
extent CRT alone or the additional maintenance chemo-
therapy with 5-FU were responsible for the observed ef-
fect. While the ESPAC-1 study did not show a survival 
benefit for adjuvant CRT, the results from the RTOG 
9704 trial indicate that gemcitabine is superior to con-
tinuous infusion of 5-FU in a combined modality ap-
proach where chemotherapy was applied before and after 
adjuvant 5-FU-based CRT in patients with cancers of the 
pancreatic head only  [21] . The RTOG 9704 clearly was not 
designed to answer the question of the importance of 
CRT in adjuvant therapy. Furthermore, 2 previously pub-
lished meta-analyses also did not show any consistent 
benefit for adjuvant CRT  [15, 16] . Thus, only well-de-
signed randomized studies using modern CRT regimens 
(including intensified modulation radiotherapy, 5-FU as 
continuous infusion or gemcitabine, and even targeted 
agents) will be able to better define the role of radiation 
treatment in the adjuvant setting  [22–25] .
 Selection of different treatment strategies according to 
prognostic factors plays an important role in many dif-
ferent types of cancer. So far, clinical trials for pancreatic 
cancer performed in the adjuvant setting have not yet 
provided a sufficient database to support risk-adapted 
treatment recommendations. Recently published data 
suggest the serum tumor marker CA 19-9 could aid in 
establishing different risk-adapted treatment strategies 
after surgical resection of pancreatic cancer  [26–28] . Ad-
ditionally, it still remains unclear if different subgroups 
of patients (for example R0/R1 resected patients, patients 
with or without nodal involvement) should be regarded 
as different entities for adjuvant treatment options.
 Especially for patients after R1 resection, the role of 
either adjuvant CRT or chemotherapy remains contro-
versial. As local control may be an important clinical goal 
for R1 resected patients, one might consider adjuvant 
CRT as a treatment of choice  [23] . However, based on data 
from randomized trials, no evidence-based recommen-
dation can be given for treatment decisions in this patient 
population. In subgroup analyses performed in patients 
after R1 resection in the ESPAC-1 study (n = 101), there 
were no significant survival differences comparing adju-
vant CRT versus no CRT or chemotherapy versus no che-
motherapy  [14, 29] . R1-resected patients included in the 
CONKO-001 trial (n = 61) experienced a prolongation in 
DFS (p  ! 0.001) and overall survival (p = 0.07) when treat-
ed with gemcitabine compared to observation only ( ta-
ble 2 )  [7] . However, the nearly identical DFS and overall 
survival for R0 and R1 resected patients receiving adju-
vant gemcitabine within the CONKO-001 study repre-
sent a quite unexpected observation ( table 2 ). One pos-
sible explanation could be the fact that there was no stan-
dardization of pathological examination and reporting 
in this multicenter study. Furthermore, the resection sta-
tus   (R0   vs.   R1)   is   also   known   as   a   factor difficult to as-
sess, especially for the posterior (retroperitoneal) margin 
 [30] . Thus, the presently available data from the ESPAC-1 
and CONKO-001 trials only reflect post hoc subgroup 
analyses performed in small patient groups. These data 
can only be regarded as hypothesis generating and de-
finitive recommendations can therefore not be expected. 
Nevertheless, further investigation of these arising ques-
tions in prospective clinical trials is strongly recom-
mended.
 In conclusion, several randomized trials – as well as 
our meta-analysis – support the benefit from adjuvant 
chemotherapy with either 5-FU/folinic acid or gemcitabi-
ne as the treatment of choice after resection of pancreatic 
cancer. While adjuvant chemotherapy clearly improves 
DFS, its effect on long-term survival still has to be veri-
fied. The currently available data do not allow a definitive 
conclusion on the importance of modern CRT in the ad-
juvant treatment of pancreatic cancer. 
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